BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Medicinal products that affect the renin-angiotensin(-aldosterone) system (RAS/RAAS): realisation of the EU Commission's implementing decision

2014.11.13

Active substance: ACE-Hemmer | Angiotensin-II-Rezeptor-Antagonisten | Aliskiren

In its notice of 31 October 2014, the Federal Institute for Drugs and Medical Devices (BfArM) has ruled the realisation of the corresponding implementing decision (2014) 6371 of the EU Commission.

To the risk assessment procedure (available in German only)

For details on the procedure please click on the following link to the homepage of the European Medicines Agency (EMA):

Renin-angiotensin-system (RAS)-acting agents